

Corporate Medical Policy

Infertility Services

(Effective Date: 1/1/2026)

Table of Contents

Description of Procedure or Service

Benefit Application

Policy Statement

Covered

Required Documentation

Policy Guidelines

Background

Regulatory Status

Codes

Scientific References

Policy Implementation and Updates

Description of Procedure or Service

Infertility is defined as the inability to conceive pregnancy within a 12-month period for individuals under age 35 (6 months for persons aged 35 or older) through unprotected intercourse or artificial insemination. Infertility may also be established through evidence of medical history and diagnostic testing. Infertility includes the need for medical intervention to conceive pregnancy either as an individual or with a partner, except following voluntary sterilization.

Iatrogenic Infertility is an impairment of fertility by surgery, radiation, chemotherapy, or other medical treatment affecting reproductive organs including gonadotoxic therapies, or ovary or testicle removal for treatment of disease.

In vitro fertilization (IVF) is a method of assisted reproduction that involves combining an egg with sperm in a laboratory dish. If the egg fertilizes and begins cell division, the resulting embryo may be transferred into the uterus where it may implant in the uterine lining and further develop or be cryopreserved for later transfer. A cycle of IVF is defined as stimulation of ovaries, oocyte retrieval, and embryo transfer or preservation.

Artificial Insemination is a surgical procedure for the introduction of sperm or semen into the vagina, cervix, or uterus to produce pregnancy.

Assisted reproductive technology (ART) includes all fertility treatments in which either eggs or embryos are handled. In general, ART procedures involve surgically removing eggs from the ovaries, combining them with sperm in the laboratory, and returning them to the birthing person's body or donating them to another person. They do NOT include treatments in which only sperm are handled (i.e., intrauterine or artificial - insemination) or procedures in which a birthing person takes medicine only to stimulate egg production without the intention of having eggs retrieved.

Benefit Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Plan for availability of coverage.

Infertility

Diagnosis and treatment of infertility is covered and is specific to procedures listed below except as shown in the Not covered section below.

- Artificial insemination is a surgical procedure for the introduction of sperm or semen into the vagina, cervix, or uterus to produce pregnancy. Artificial insemination procedures and related services and supplies may be covered when medically necessary, including:
 - Intravaginal insemination (IVI), except if performed outside of clinical setting
 - Intracervical insemination (ICI)
 - Intrauterine insemination (IUI)
- Fertility drugs

Iatrogenic Infertility

- Standard fertility preservation procedures (retrieval of and freezing of eggs or sperm) for members who have been diagnosed with iatrogenic infertility include:
 - collection of sperm
 - cryopreservation of sperm
 - cryopreservation of embryo
 - collection of oocyte
 - cryopreservation of oocyte
 - benefits limited to up to 12 months of storage of sperm, oocytes and embryo

Note: High Option plans include standard fertility preservation procedures as well as Assisted Reproductive Technologies and In Vitro Therapy for Iatrogenic Infertility when qualifying criteria are met.

In Vitro Fertilization (IVF) (High Option)

- Oocyte identification and retrieval
- Sperm preparation
- Insemination of oocytes
- Embryo culture
- Embryo biopsy and preimplantation genetic testing when determined to be medically necessary
- Intrauterine embryo transfer
- Cryopreservation of sperm and ova (gametes) and embryos for future transfer
- Storage of cryopreserved gametes and embryos for 1 year
- Fertility drugs

In Vitro Fertilization is limited to \$25,000 annual benefit maximum. Dollar limits include procedures, supplies, and any related facility or anesthesia services. (High Option)

Policy Statement

G.E.H.A will provide coverage for infertility treatment when it is determined to be medically necessary because the medical criteria and guidelines as documented below have been demonstrated.

Diagnosing Infertility

The following are proven and medically necessary for diagnosing and treating infertility:

- A. Antisperm antibodies
- B. Antral follicle count
- C. Genetic screening tests:
 - 1. Cystic fibrosis gene mutations
 - 2. Karyotyping for chromosomal abnormalities
 - 3. Y-chromosome microdeletion testing
- D. Hormone level tests:
 - 1. Anti-mullerian hormone (AMH)
 - 2. Estradiol
 - 3. Follicle stimulating hormone (FSH)
 - 4. Luteinizing hormone (LH)
 - 5. Progesterone
 - 6. Prolactin
 - 7. Testosterone (total and free)
 - 8. Thyroid stimulating hormone (TSH)
- E. Hysterosalpingogram (HSG)
- F. Diagnostic hysteroscopy
- G. Diagnostic laparoscopy with or without chromotubation
- H. Leukocyte count in semen
- I. Pelvic ultrasound (transabdominal or transvaginal)
- J. Post ejaculatory urinalysis
- K. Scrotal, testicular or transrectal ultrasound
- L. Semen analysis
- M. Sonohysterogram or saline infusion ultrasound
- N. Testicular biopsy
- O. Vasography

Note: Pre-Implantation Genetic Testing requires preauthorization. [Pre-Implantation Genetic Testing Policy Link](#). The most reliable method is to use the [provider portal](#) or the provided phone number on the member's insurance ID card.

Artificial Insemination

Artificial insemination [Intravaginal insemination (IVI), Intracervical insemination (ICI), Intrauterine insemination (IUI)] is considered medically necessary for the treatment of infertility for any of the following:

- A. Infertility with male factor fertility problems (2 or more semen analyses, measured 4 weeks apart, have 1 or more variables below the 5th percentile); or

- B. Unexplained infertility problems; or
- C. Minimal to mild endometriosis; or
- D. Medically refractory erectile dysfunction or vaginismus preventing intercourse; or
- E. HIV positive and undergoing sperm washing; or
- F. Clomiphene-citrate-stimulated artificial insemination (intra-cervical insemination or IUI) for infertile females with WHO Group II ovulation disorders such as polycystic ovarian syndrome who ovulate with clomiphene citrate but have not become pregnant after ovulation induction with clomiphene.

If a member meets appropriate clinical scenarios with supporting provider documentation, approval may be granted for IUI treatments with oral medications and triggers.

Benefits for medications related to the treatment of fertility preservation are considered under the Outpatient Prescription Drug benefit or under the Pharmaceutical Products. Check the member specific benefit plan document for inclusion or exclusion. For medication related benefit questions, please contact G.E.H.A at (800) 821-6136. Authorization of a fertility medication does not imply authorization of any related fertility procedures.

Assisted Reproductive Technologies (ART) (High Option)

Assisted Reproductive Technologies (ART) are considered medically necessary for the following conditions:

- A. Unexplained infertility
- B. Diminished ovarian reserve
- C. Tubal factor infertility
- D. Male factor infertility
- E. Endometriosis
- F. Ovulatory dysfunction
 1. When ovulation induction has not resulted in conception
 2. Poor response to ovulation induction
 3. Hyper-response to ovulation induction where there is a risk for ovarian hyperstimulation or a multiple gestation
- G. Failure to achieve conception after 3 unsuccessful attempts with IVI, IUI or ICI treatment.
- H. Iatrogenic Infertility (High Option)

When Assisted Reproductive Technologies (ART) are not covered:

- A. When using autologous oocytes in the setting of a very poor or futile prognosis; OR
- B. When there is a failure to respond to ovarian stimulation (e.g., as demonstrated by failure to achieve at least 1 follicle >12 mm in diameter); OR
- C. ART cycle does not demonstrate the attainment of at least 1 embryo suitable for transfer; OR
- D. Lack of viable spermatozoa; OR
- E. Ovarian failure where a couple is attempting conception with their own gametes; OR
- F. Recurrent aneuploidy or ≥ 5 unexplained losses; OR
- G. Greater than 2 consecutive ART cycles without adequate egg quality or production, fertilization and/or embryo quality or development; OR

Intracytoplasmic Sperm Injection (ICSI) (High Option)

Intracytoplasmic Sperm Injection (ICSI) ICSI is considered medically necessary for the following:

- A. Male factor infertility
 - 1. "Male factor" infertility is an alteration in sperm concentration and/or motility and/or morphology in at least two sperm analyses, collected 4 weeks apart.
- B. After failed conventional insemination
- C. Failed attempts at traditional IVF or conventional insemination when the quality of the ovarian stimulation was not the cause of failure.
- D. Cases of IVF using preimplantation genetic testing for monogenic disorders (when a covered benefit) or structural rearrangements.
- E. When using previously cryopreserved oocytes.
- F. When using TESE/PESE (surgically) derived sperm
- G. Recurrent molar pregnancies

When ICSI is not covered:

- A. Unexplained infertility
- B. Advanced maternal age
- C. Low oocyte yield
- D. Repeat IVF attempts after documented poor ovarian stimulation
- E. Routine IVF
- F. When the diagnosis is limited exclusively to teratospermia unless <2% strict morphology has been demonstrated on at least two semen analyses.
- G. In the setting of PGT-A

Male Factor Infertility (High Option)

Varicocele Repair/Varicocelectomy

- A. Surgical varicocelectomy is indicated in men attempting to conceive who have palpable varicocele(s), infertility, and abnormal semen parameters, except for azoospermic men.
- B. Varicocelectomy is not indicated for men with non-palpable varicoceles detected solely by imaging.
- C. Varicocelectomy is not indicated for men with clinical varicocele and non-obstructive azoospermia.

Sperm Retrieval

- A. Surgical sperm aspiration, (Microsurgical epididymal sperm aspiration (MESA), Percutaneous epididymal sperm aspiration (PESA), Open testicular biopsy (TESE), Percutaneous testicular sperm aspiration (TEFNA) or Percutaneous testicular needle biopsy) is indicated for obstructive azoospermia in the setting of:
 - 1. Congenital absence of the vas deferens (carrier of cystic fibrosis gene (Jaffe, 1994), OR
 - 2. Infection, OR
 - 3. Vasectomy, OR
 - 4. Trauma.
- B. Men with retrograde ejaculation (RE) may be treated with:

1. Sympathomimetics and alkalization of urine with or without urethral catheterization, OR
 2. Induced ejaculation, OR
 3. Surgical sperm retrieval.
- C. Men with aspermia may be treated with:
1. Surgical sperm extraction, OR
 2. Induced ejaculation (sympathomimetics, vibratory stimulation or electroejaculation).

Note: Surgical sperm aspiration is not indicated in the absence of azoospermia.

Cryopreservation (High Option, apart from Iatrogenic Infertility)

Embryo or mature oocyte cryopreservation is considered medically necessary for the following:

- A. Prevention of ovarian hyperstimulation syndrome
- B. Elective single embryo transfer to freeze and store supernumerary embryos or otherwise when there are supernumerary embryos
- C. Pre-implantation genetic testing
- D. Presence of poor endometrial development
- E. When there is a failure to obtain sperm at the time of a fresh ART cycle at egg retrieval
- F. Freeze only cycles:
 1. All embryos are cryopreserved with the intent for subsequent transfer within a 12month time period
- G. Iatrogenic Infertility (see criteria for Iatrogenic Infertility)

Sperm cryopreservation is considered medically necessary for the following:

- A. Medically necessary surgically obtained (TESE, PESE, etc.) sperm
- B. Iatrogenic infertility (see criteria for Iatrogenic Infertility)

When embryo or mature oocyte cryopreservation is not covered:

- A. For the purpose of embryo or oocyte accumulation or banking
- B. Fresh oocyte retrievals are not indicated when previously frozen oocytes (M2) or embryo of at least BB grading quality (or equivalent) are available for transfer and if tested, are genetically normal. A fresh cycle is indicated when there are <8 previously frozen oocytes (M2) as long as those oocytes are not being used in conjunction with a fresh cycle.

Elective Single Embryo Transfer (eSET) (High Option)

- A. Elective single embryo transfer (eSET) is considered medically necessary for all patients with a favorable prognosis.
- B. Recommended for favorable prognosis is the use of expanded day 5 or 6 blastocysts with well defined inner-cell mass and trophectoderm as defined by the individual embryology laboratory.

When treatment for infertility is not covered:

- A. Gamete intrafallopian transfer (GIFT) and zygote intrafallopian transfer (ZIFT)
- B. Multiple Embryo Transfer
- C. Charges for gestational carrier or surrogacy, including antenatal appointments and labor/delivery services

- D. Charges for procedures to collect, analyze, manipulate, or otherwise treat gametes (sperm and ova) when the partner or donor who produces the gamete is not a covered member on the plan
- E. Cost of donor egg
- F. Cost of donor sperm
- G. Elective preservation, such as egg freezing sought due to natural aging
- H. Fertility drugs, provided by facilities or physicians, including ovulation induction cycles while on injectable medication to stimulate the ovaries. Fertility drugs must be obtained through the pharmacy benefits, see Prescription Drug Benefits and Specialty Drug Benefits within your plan brochure. Medications will not be covered when dispensed by other sources, including physician offices, home health agencies and outpatient hospitals.
- I. Genetic counseling
- J. Infertility services after voluntary sterilizations
- K. Reversal of voluntary surgical sterilizations
- L. Services and supplies related to non-covered ART procedures.
- M. Treatments such as artificial insemination, assisted reproductive technology, and/or in vitro fertilization prior to establishing diagnosis of infertility.

The following are unproven and not medically necessary for diagnosing and/or treatment of infertility:

- A. Co-culture of embryos
- B. Computer assisted sperm analysis (CASA)
- C. Cryopreservation of immature oocytes, ovarian tissue or testicular tissue
- D. EmbryoGlue
- E. Hyaluronan binding assay (HBA)
- F. In vitro maturation (IVM) of oocytes
- G. Inhibin B
- H. Postcoital cervical mucus penetration test
- I. Reactive oxygen species (ROS) testing
- J. Sperm Acrosome reaction test
- K. Sperm capacitation test
- L. Sperm DNA integrity/fragmentation tests
- M. Sperm penetration assays
- N. Uterine/endometrial receptivity testing
- O. Treatments to improve uterine/endometrial receptivity.

Iatrogenic Infertility

Benefits are available for fertility preservation for medical reasons that cause irreversible infertility. Services include the following procedures, when provided by or under the care or supervision of a Physician:

- A. Collection of sperm
- B. Cryopreservation of sperm
- C. Ovarian stimulation, retrieval of eggs and fertilization
- D. Oocyte cryopreservation

E. Embryo cryopreservation

Benefits for medications related to the treatment of fertility preservation are considered under the Outpatient Prescription Drug benefit or under the Pharmaceutical Products. Check the member specific benefit plan document for inclusion or exclusion. For medication-related benefit questions, please contact G.E.H.A at (800) 821-6136. Authorization of fertility medication does not imply authorization of any related fertility procedures.

Benefits are limited to one successful cycle of fertility preservation for Iatrogenic Infertility per covered person during the entire period of time enrolled for coverage under the healthcare plan.

Successful fertility preservation cycle includes:

1. 8-10 mature oocytes obtained within no more than 3 attempts of retrieval or
2. 3-4 vials of sperm obtained within no more than 3 attempts of separate sperm extraction sessions. (ASRM, 2019)

When treatment for Iatrogenic Infertility is not covered:

- A. Cryopreservation of immature oocytes, ovarian tissue or testicular tissue
- B. Embryo transfer (unless under the High Option Plan)
- C. Long term storage costs (greater than 1 year)
- D. Infertility treatment after voluntary sterilization

Required Documentation

Medical notes documenting the following, when applicable:

- Initial history and physical
- All clinical notes including rationale for proposed treatment plan
- All ovarian stimulation sheets for timed intercourse, IUI, and/or IVF cycles
- All embryology reports
- All operative reports
- Laboratory report FSH, AMH, estradiol, and any other pertinent information
- Ultrasound report antral follicle count and any other pertinent information
- HSG report
- Semen analysis

Policy Guidelines

According to the American Society of Reproductive Medicine (ASRM) and American Society for Clinical Oncology (ASCO) medical practices and guidelines fertility preservation services are defined as those procedures indicated for an individual facing infertility due to chemotherapy, pelvic radiotherapy, or other surgical procedures expected to render one permanently infertile (e.g., hysterectomy, oophorectomy)

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO): According to the ASCO guidelines on fertility preservation in patients with cancer, oocyte and embryo cryopreservation are considered standard practice (Oktay et al., 2018). ASCO purports that the field of ovarian tissue cryopreservation (OTC) is advancing quickly and may evolve to become standard therapy in the future.

AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM): An ASRM committee issued an opinion that OTC and reimplantation of tissue is experimental, although it may be an option for individuals in which gonadotoxic treatment is necessary immediately or among prepubertal girls (Hayes Report: Health Technology, 2021).

AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM): The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated. Although some earlier single-center studies reported higher live birth rates after PGT-A in favorable-prognosis patients, recent multicenter, randomized control trials in women with available blastocysts concluded that the overall pregnancy outcomes via frozen embryo transfer were similar between PGT-A and conventional in vitro fertilization. The value of PGT-A to lower the risk of clinical miscarriage is also unclear, although these studies have important limitations.

Background

Infertility affects approximately 186 million people worldwide and 8-12% of couples of reproductive age. Therefore, a comprehensive diagnostic evaluation of infertility is crucial to achieving improvements in targeted prevention and treatment outcomes (Wasilewski, 2020).

Poor Prognosis and Futility

Examples where continued treatment may be futile: (ASRM, 2019)

FSH level ≥ 15 mIU/mL; OR AMH level < 0.2 ng/mL (LaMarca, 2013); OR Antral follicle count < 3 (ASRM, 2021(a); LaMarca, 2013). Lack of viable spermatozoa. Ovarian failure where a couple is attempting conception with their own gametes. Numerous ART cycles without adequate egg production, fertilization and/or embryo development.

National data from the SART registry 2019 demonstrates that the cumulative live birth per intended retrieval resulting in live births decreased progressively from: 55.0% in females younger than 35 years; 41.0% for females aged 35-37 years; 26.8% for females aged 38-40 years; 13.4% for females aged 41-42; and 4.14% for females over the age of 42. The age-related decline in fertility is accompanied by a significant increase in the rates of aneuploidy and spontaneous abortion. (SART, 2020)

Poor Prognosis: “Very poor prognosis” refers to treatment for which the odds of achieving a live birth are very low but not nonexistent ($>1\%$ to $<5\%$ per cycle). (ASRM, 2019)

Aneuploidy

Female fecundity decreases with increasing age. Aging chromosome segregation errors during meiotic division are increasingly common and lead to the production of oocytes an incorrect number of chromosomes, referred aneuploidy. trophectoderm biopsies $>15,000$ blastocysts have shown that the rate of aneuploidy steadily increases after age 31 and reaches 85% at age 43 (Franasiak, 2014).

To determine an 85% risk for aneuploidy, a healthcare professional typically uses a prenatal screening test, like a combined first-trimester screening (cFTS), which combines maternal blood tests measuring specific markers (like PAPP-A and free β -hCG) with an ultrasound measurement of the fetal nuchal translucency (NT), and interprets the results based on the mother's age to calculate a risk score; a score

indicating an 85% chance of aneuploidy would be considered "high risk" and usually warrants further diagnostic testing like chorionic villus sampling (CVS) or amniocentesis to confirm the diagnosis

The risk calculation considers maternal age, ultrasound findings (like NT thickness), and levels of specific biochemical markers in the blood (Russo, 2014) (Harris et.al., 2018).

Treatment in the Natural Cycle

Natural cycle treatment assumes: Normal ovulatory function with spontaneous (unstimulated) ovulation; At least one patent fallopian tube; Normal uterine cavity. Treatment options in the natural cycle encompass Timed coitus, Cervical insemination, Intrauterine insemination (IUI) and assisted reproductive technologies (ART). Cervical insemination in the natural cycle may be beneficial in cases involving sexual dysfunction. Intrauterine insemination may be useful in cases involving cervical trauma (e.g., cervical ablation, following a wide cervical cone biopsy). There is no evidence that absent sexual dysfunction or cervical trauma, natural cycle (i.e., no ovarian stimulation) IUI has any benefit over appropriately timed heterosexual intercourse. (Helmerhorst, 2005; ASRM, 2020). Natural cycle IUI may be considered in the setting of donor insemination when no other infertility factor is present.

Male Factor Infertility

World Health Organization Reference Limits for Human Semen Characteristics: Semen Parameter: One-Sided Lower Reference Limit (Fifth Centiles With 95% Confidence Intervals): Semen Volume 1.4 mL (1.3-1.5) Total Sperm Number 39 million per ejaculate (35-40) Sperm Concentration 16 million/mL (15-18 million/mL) Vitality 54% Live (50-56%) Progressive Motility 30% (29-31%) Total Motility (Progressive + Non-Progressive) 39% (40-43%) Morphologically Normal Forms 4.0% (3.9-4.0)

- Mild Male Factor: abnormalities in the semen analysis where the sperm concentration is ≥ 10 million/mL but < 15 million/mL and/or progressive motility is $\geq 30\%$ but $< 40\%$ or ≥ 5 million total motile sperm
- Moderate Male Factor: abnormalities in the semen analysis where the sperm concentration is ≥ 5 million/mL but < 10 million/mL and/or progressive motility is $\geq 25\%$ but $< 30\%$
- Severe Male Factor: abnormalities in the semen analysis where the sperm concentration is < 5 million/mL or sperm preparation techniques result in a sperm concentration of < 1 million motile sperm/mL (Schlegel, 2020)
- Isolated teratospermia is considered a male factor when there is $< 2\%$ normal morphology on at least two semen analyses 1-4 weeks apart.

Surgical Sperm Aspiration

Surgical sperm aspiration is the surgical removal of sperm to obtain high quality sperm in adequate numbers to be used in assisted reproductive technology cycles and/or cryopreservation. Approximately 5%-10% of males evaluated for infertility are azoospermic. (Schlegel, 1997; Schlegel, 1999)

Elective Single Embryo Transfer (eSET)

Assisted reproductive technology (ART) poses a major risk of multiple pregnancy and birth that is associated with adverse maternal and infant outcomes. The principal reason behind the large number of multiple pregnancies after invitro fertilization (IVF) is the practice of transferring more than one embryo within the uterus to maximize pregnancy rates. (ASRM, 2012; Criniti, 2005; Pandian, 2009). Twin pregnancies and higher order gestations are associated with an increased risk of Preeclampsia,

Hypertension, Preterm labor, Premature rupture of membranes, Low birth weight (<2,500 g), Operative delivery, Fetal death and/or Cerebral palsy. (Mullin, 2010)

Even though eSET requires subsequent frozen embryo transfer cycle(s) if the initial fresh cycle is unsuccessful, it is prudent to promote elective single blastocyst embryo transfer as a means of reducing the frequency of multiple gestations and the associated risks of poor maternal and birth outcomes. (Johnson, 2013; Sunderam, 2012). Numerous countries have adopted regulations that mandate eSET resulting in a twin gestation rate of <5%. Pregnancy rates for eSET are comparable to multiple embryo transfer. (Thurin, 2004). Although pregnancy outcome diminishes with increasing maternal age, all age groups should be considered for blastocyst stage eSET (Niinimaki, 2012; Kato, 2012) particularly in the context of preimplantation genetic testing or other technologies that enhance the embryo selection process.

Strategies to improve live birth have primarily focused on maximizing embryo selection and endometrial synchrony. These strategies include PGT-A, freezing only embryo transfer cycles, endometrial synchrony testing, and time lapse imaging and other noninvasive embryo testing strategies. There is currently a lack of robust and consistent evidence that these strategies improve the chances of achieving a live birth. In addition, while strategies to improve live birth are aimed at improving the live birth success of each embryo transfer, they are not necessary to reduce multiple gestation. Performing SET without additional embryo or endometrial testing reduces the multiple gestation rate down to the background 1–2% risk of monozygotic twins in ART (Gardner 2004, Styer 2008, Crinit 2005). Single embryo transfer, regardless of additional testing, should be considered the gold standard to reduce multiple gestation. Given the lack of robust evidence or conflicting evidence for many of these tests to improve clinical outcomes, they are currently not routinely recommended as a strategy to increase SET (ASRM 2022)

Embryo Banking and Use of Frozen Embryos

There is no evidence in medical literature to support the practice of repeated ART cycles for the purpose of accumulating (banking) embryos for later use (egg retrievals without a fresh or frozen embryo transfer) with the exception of freeze all cycles for medical necessity. It is clinically appropriate and cost effective to utilize all frozen embryos for transfer prior to another fresh ART cycle. (Forman, 2013; Richter, 2006; Shapiro, 2011, 2013).

Cryopreservation

Cryopreservation is freezing at a very low temperature, such as in liquid nitrogen (-196C) to keep embryos, eggs, or sperm viable. Sub-zero temperature is not a physiological condition for cells and water ice crystals represent the main problem since they induce cell death, principally in large cells like oocytes, which have a meiotic spindle that degenerates during this process. Significantly, cryopreservation represents an option for fertility preservation in patients who develop gonadal failure for any condition and those who want to freeze their germ cells for later use (Estudillo, et. al., 2021).

Cryopreservation of gonadal tissue

Ovarian tissue cryopreservation (OTC) involves harvesting and freezing ovarian tissue, thus preserving oocytes in primordial follicles located in the ovarian cortex. The ovarian tissue can subsequently be auto transplanted after gonadotoxic treatment has ended.

A low-quality, limited body of evidence suggests that OTC and transplantation have the potential to restore ovarian function and may result in preserved fertility in patients who have undergone gonadotoxic cancer treatment. Limitations to the body of evidence include an evidence base composed of 2 poor-quality cohort studies, 6 poor-quality single-arm studies, and 1 very-poor-quality cross-sectional study. Better quality prospective studies ensuring that all patients are followed after receiving transplantation would provide better assurance that the effects of OTC and subsequent transplantation on fertility and pregnancy outcomes reported herein are representative.

Cryopreservation, storage and thawing of testicular tissue is considered unproven in the treatment of infertility (ASRM, 2014).

Cryopreservation of testicular tissue in higher risk prepubertal males is feasible, but still experimental. Female fertility preservation is more complex, requires more invasive procedures, and can delay initiation of treatment due to the requirement for hormone stimulation of follicles prior to harvesting (Romao & Lorenzo, 2017).

Co-culture of embryos

Studies describe different techniques of co-culture, but no standardized method of co-culturing has been defined. Further studies are necessary to support the effects of co-culture on clinical outcomes.

Co-culture is a process by which embryos develop on culture containing cells grown from the patient's own endometrium (uterine lining). The endometrial cells collected by the physician are grown in the Embryology Laboratory. These cells are thawed prior to oocyte retrieval. Then, the embryos are placed with the cultured endometrial cells to support embryonic development (Weill Cornell Medicine, 2023).

Le Saint et. al. (2019) performed an interventional, randomized, double-blind study that took place at Clinique Ovo from March 2013 to October 2015 and included 207 healthy patients undergoing an IVF of which 71 were excluded before randomization. On the previous cycle, all participants underwent an endometrial biopsy at D5 to D7 post-ovulation, following which the endometrial cells were prepared for (AECC) autologous endometrial cell co-culture.

Results

The data demonstrated that AECC significantly increased the incidence of good-quality blastocysts compared with culture in conventional media (42.6% versus 28.4%, $P < 0.001$). No significant differences were found in pregnancy and live birth rates.

Conclusion

This study demonstrated the benefits of AECC on blastocyst quality compared with conventional embryo culture medium, in a broader category of patients referred to ART as opposed to other studies that concentrated on specific causes of infertility only. However, limitations of the study design should be taken into consideration; the analysis was performed using embryos rather than patients and a followup of children born following the treatments could not be conducted.

Computer Assisted Sperm Analysis (CASA)

There is insufficient evidence to permit conclusions regarding the use of this sperm function test. Study results to date have demonstrated low specificity, low sensitivity and a high rate of false positives.

The evaluation of sperm characteristics is part of the diagnostic process for infertile couples. Computer aided semen analysis (CASA) uses a hardware- and software-based system to determine characteristics of sperm, including the kinematics/motility, concentration, and morphology.

In a recent systematic review conducted by Finelli et. al. (2021), the validity and reliability of computer aided semen analyzers in performing semen analysis was examined. A total of 14 studies were included. Our results showed a high degree of correlation for sperm concentration and motility when analysis was performed either manually or by using a CASA system. However, CASA results showed increased variability in low (<15 million/mL) and high (>60 million/mL) concentration specimens, while sperm motility assessment was inaccurate in samples with higher concentration or in the presence of nonsperm cells and debris. Morphology results showed the highest level of difference, due to the high amount of heterogeneity seen between the shapes of the spermatozoa either in one sample or across multiple samples from the same subject. Overall, the study suggests CASA systems as a valid alternative for the evaluation of semen parameters in clinical practice, especially for sperm concentration and motility. However, further technological improvements are required before these devices can one day completely replace the human operator. Artificial intelligence-based CASA devices promise to offer higher efficiency of the analysis and improve the reliability of results.

EmbryoGlue

There is insufficient evidence supporting the clinical utility of EmbryoGlue. Further studies are needed to support improved clinical outcomes measures.

EmbryoGlue is a hyaluronan-enriched embryo transfer (ET) medium which aids in implantation of embryos, hence, improves pregnancy rates in in vitro fertilization-ET cycles (IVF-ET).

Singh, et. al. (2015) conducted a prospective case-control study at an assisted reproductive center of a tertiary care hospital. Forty-two women undergoing IVF, embryos were transferred into 50 µL of EmbryoGlue for 10 min prior to transfer inside uterine cavity. In the control group (n = 42), embryos were transferred to conventional blastocyst culture medium. Clinical pregnancy rate in the study group was 7% higher than in the control group. The difference, however, was not statistically significant. In addition, no improvement in implantation rates was observed in the study group. However, significant difference (P = 0.04) in clinical pregnancy rate was observed with the EmbryoGlue in patients with previous IVF failure. In the study group, 50% of patients (6/12) with previous IVF failure had successful implantation, but in the control group none of the patients (0/11) with previous implantation failure could achieve pregnancy. It was concluded; it is difficult to conclude a favorable role of EmbryoGlue in IVF-ET cycles with a good prognosis. However, in patients with recurrent implantation failure, it may be considered as a useful transfer medium.

Hyaluronan binding assay (HBA)

There is insufficient evidence supporting the clinical utility of HBA testing as an advanced sperm selection technique. More studies are needed to support improved outcomes (i.e., increased successful pregnancies with delivery of liveborn children).

In a prospective study conducted by Lazarevic et. al. (2010), the question was examined: Hyaluronan binding assay (HBA) versus sperm penetration assay (SPA): Can HBA replace the SPA test in male partner screening before in vitro fertilization?

Semen samples from 26 infertility couples were analyzed. Both, normal and male factor patients were included. The data obtained in this study showed no statistically significant relationship between the HBA and SPA results. The mean HBA scores 76.3%, 61.3% and 76.8% were statistically not significantly different as compared to patients with negative (<5), grey zone (5–8) and for positive (>8) sperm capacitation index values.

It was concluded that the HBA is not predictive of the results of the SPA. Therefore, HBA test does not reduce the need for and cannot replace the SPA test in male partner screening prior to infertility treatment.

In vitro maturation of oocytes

Although preliminary results with in vitro maturation are promising, studies to date show that implantation and pregnancy rates are significantly lower than those achieved with standard IVF. Further evidence from well-designed trials is needed to determine the long-term safety and efficacy of the procedure.

In vitro maturation (IVM) is a technique used to induce immature oocytes collected in different periods of embryonic growth.

A prospective study by Carles, et. al. (2023) evaluated the competence of our in vitro maturation autologous co-culture method on the maturation and developmental potential of immature oocytes obtained from stimulated IVF-ICSI cycles, to obtain additional embryos for the couple as a rescue system to increase the chances of cumulative pregnancy. Fourteen couples managed in IVF-ICSI in our center, from January to March 2020. Thirty-eight oocytes, identified as immature after cumulus-oocyte complexes (COC) stripping for ICSI, were placed in our in vitro maturation medium with the addition of autologous cumulus cells. Oocytes that had reached the metaphase II stage after a maximum of 36 hours of maturation were microinjected. The fertilization and embryonic development potential of the in vitro matured oocytes were compared to those of 148 in vivo matured "siblings" oocytes from the same oocyte retrieval, and then also compared to those of 127 in vivo matured oocytes from different patients (control group). No significant difference was found in the main and secondary criteria of the study compared to the "siblings" in vivo matured oocytes from the same oocyte retrieval. However, a significant difference was obtained on the rate of early cleavage and useful blastulation when our cohort was compared to mature in vivo oocytes from different patients (control group).

Conclusion: This study has shown that after incubation in vitro maturation autologous cumulus cell coculture with cumulus-oocyte cells, immature oocytes recovered during stimulated cycles can give rise to competent oocytes, i.e., capable of being fertilized, of cleaving, and of developing into embryos up to the blastocyst stage. Our study therefore seems to be in the direction of a favorable use of these immature oocytes obtained after stimulated IVF-ICSI cycles. The continuation of this study by including a larger number of oocytes is necessary in order to evaluate the real contribution of this technique in routine.

Inhibin B

There is insufficient evidence to permit conclusions regarding the use of inhibin B as a measure of ovarian reserve. More studies are needed to support improved outcomes (i.e., increased successful pregnancies with delivery of liveborn children) with the use of this test.

The higher level of serum inhibin B of reproductive age women is one of the important factors to maintain a low level of serum FSH. However, with the increase of their age, both the quality and quantity of ovarian follicles decrease, the level of serum inhibin B decreases gradually, and the inhibitory effect on FSH will be weakened, which is also one of the important reasons for the progressive increase of their serum FSH levels. Inhibin B may have certain clinical application potential in assessing the progress of ovarian aging, diagnosing premature ovarian failure (POF) or premature ovarian insufficiency (POI), evaluating the ovarian function of cancer survivors, and predicting assisted reproductive technology (ART) outcomes (Wen, J. et. al. 2021).

Wen, J. et.al. (2021) conducted a study aimed to define the variation trend of inhibin B in healthy women with age and explore its value in the reflection of ovarian reserve. Although the results showed a slight advantage in predicting ovarian response, more studies are needed to provide clarity of the reference range and potential value of inhibin B.

Postcoital cervical mucus penetration test

There is insufficient evidence supporting the predictive value or clinical utility of this test. More studies are needed to support improved outcomes (i.e., increased successful pregnancies with delivery of liveborn children).

The postcoital test, also known as the cervical mucous penetration assay, is designed to evaluate impaired male factors such as hyperviscosity, abnormal penile anatomy, decreased semen volume despite good sperm density, and unexplained infertility. The postcoital test is performed by examining the cervical mucus several hours after intercourse, ideally around the periovulatory phase of the female. The cervical mucus is smeared on a slide and examined microscopically for the presence of ferning within the mucus and for the quantitative presence of sperm and forward sperm motility. The role of the postcoital test continues to be a point of debate (Mohit, K. 2006).

Reactive Oxygen Species (ROS) testing

There is insufficient evidence supporting the predictive value or clinical utility of this test. Additional studies are needed to support improved clinical outcomes.

Reactive oxygen species have a significant impact on spermatogenesis as well as on sperm function. Supraphysiologic levels of ROS can affect all aspects of the semen analysis. Multiple studies have demonstrated the detrimental effects of ROS on sperm concentration, motility, morphology and ROS are implicated in sperm DNA damage and apoptosis. Conversely, other studies have demonstrated no correlation between ROS and sperm motility. Recent studies have demonstrated that ROS values have a sensitivity of 68.8% and specificity of 93.8% in diagnosing male factor infertility (infertility due to abnormal semen parameters, not female-related factors) (Ko, E. et. al. 2014).

Sperm Acrosome reaction test

There is insufficient evidence supporting the predictive value or clinical utility of this test. More studies are needed to support improved outcomes (i.e., increased successful pregnancies with delivery of liveborn children).

The acrosome reaction is induced by spermatozoa-ZP binding, right after the lytic acrosomal enzymes are released, and the spermatozoa proceed to the zonal matrix with increased flagellar motility. SpermZP binding tests including sperm-zona binding test and hemizona test (HZA) and acrosome reaction tests

have been shown to provide clinically significant information to predict IVF results. The highest specificity and sensitivity associated with sperm-ovum interaction are also provided by the sperm-ZP binding tests. Although there is a significant relation between the in vitro results of these tests and fertilization, there are problems about their utilization in routine clinical practice such as difficulties in terms of requirements for human material requirement, challenging occasionally time-consuming and expensive techniques (Fuat, K. & Baris, A. 2017).

Sperm capacitation test

There is insufficient evidence supporting the predictive value or clinical utility of this test. Additional quality studies are needed to support improved clinical outcomes.

Sperm capacitation is the set of natural physical changes that a spermatozoon undergoes to be able to fertilize the ovum. This occurs in vivo following ejaculation when the spermatozoa come into contact with the different fluids in the female genital tract.

The Cap-Score™ Sperm Function Test (Androvia LifeSciences, Mountainside, NJ), is an in vitro, laboratory-developed test designed to evaluate sperm function, particularly regarding capacitation. This assay identifies and analyzes the localization patterns of the ganglioside GM1 to evaluate the fertilizing ability of sperm. Conducting a Cap-Score test involves the incubation of sperm in medium containing capacitating stimuli (Cap) and non-capacitating (non-Cap) medium. The sperm that react to the capacitation stimuli are identified by specific GM1 localization patterns. The final data, called the “CapScore” reports the proportion of sperm within a sample that display the localization patterns that correspond with capacitation (Moody, 2017)

Sperm DNA integrity/fragmentation tests

There is insufficient evidence supporting the predictive value or clinical utility of this test. Prospective studies directly evaluating the impact of DNA fragmentation testing on the management of infertility are needed.

According to ASRM:

“For a diagnostic test to be clinically useful the results must be reproducible, applicable to a given patient, and change the management of the patient. For tests of DNA integrity to be clinically important there must be an association of sperm DNA damage with reproductive outcomes” (ASRM, 2013).

At the current time, there is a lack of studies demonstrating that sperm DNA fragmentation testing results in improved clinical outcomes (improves the likelihood of conception).

Sperm penetration assays

There is insufficient evidence supporting the clinical utility of this test in lieu of newer technologies for treating male infertility.

ASRM contributed the following recommendation to Choosing Wisely®:

Don't perform advanced sperm function testing, such as sperm penetration or hemizona assays, in the initial evaluation of the infertile couple. Studies document that extreme variability exists among these tests, with very little correlation between results and outcomes. They have also been shown not to be cost-effective and often lead to more expensive treatments (ASRM, 2019).

Uterine/endometrial receptivity testing

There is insufficient evidence supporting the safety and efficacy of uterine receptivity testing and/or treatment. More studies are needed to support improved outcomes such as successful pregnancies with delivery of liveborn children.

In a recent study by Hoogenhuijze et. al. (2021) the SCRaTCH trial was a non-blinded randomized controlled trial in women with one unsuccessful IVF/ICSI cycle and assessed whether a single endometrial scratch using an endometrial biopsy catheter would lead to a higher live birth rate after the subsequent IVF/ICSI treatment compared to no scratch. The study took place in 8 academic and 24 general hospitals. Participants were randomized between January 2016 and July 2018 by a web-based randomization program. Secondary outcomes included cumulative 12-month ongoing pregnancy leading to live birth rate.

After the fresh transfer, 4.6% more live births were observed in the scratch compared to control group (110/465 versus 88/461, respectively, risk ratio (RR) 1.24 [95% CI 0.96-1.59]). These data are consistent with a true difference of between -0.7% and +9.9% (95% CI), indicating that while the largest proportion of the 95% CI is positive, scratching could have no or even a small negative effect. Biochemical pregnancy loss and miscarriage rate did not differ between the two groups: in the scratch group 27/153 biochemical pregnancy losses and 14/126 miscarriages occurred, while this was 19/130 and 17/111 for the control group (RR 1.21 (95% CI 0.71-2.07) and RR 0.73 (95% CI 0.38-1.40), respectively). After 12 months of follow-up, 5.1% more live births were observed in the scratch group (202/467 versus 178/466), of which the true difference most likely lies between -1.2% and +11.4% (95% CI).

This study was not blinded. Knowledge of allocation may have been an incentive for participants allocated to the scratch group to continue treatment in situations where they may otherwise have cancelled or stopped. In addition, this study was powered to detect a difference in live birth rate of 9%.

Regulatory Status

Infertility treatment is a procedure and, therefore, not subject to FDA regulation. However, any medical devices, drugs, biologics, or tests used as a part of this procedure may be subject to FDA regulation.

Applicable Codes

The following list of codes are intended for reference purposes only, is not an all-inclusive code listing.

Applicable codes include but are not limited to:

Service Type	Code	Description
Diagnosis		
Antisperm Antibodies	89325	Antisperm antibody test
Antral Follicle Count	76830	Ultrasound, transvaginal
	76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete

	76857	Ultrasound, pelvic (nonobstetric), real time with image documentation; limited or follow-up (e.g., for follicles)
Genetic screening tests:		
Cystic fibrosis gene mutations		
	81220	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; common variants (e.g., ACMG/ACOG guidelines)
	81223	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; full gene sequence
	81224	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; intron 8 poly-T analysis (e.g., male infertility)
Karyotyping for chromosomal abnormalities	88230	Tissue culture for non-neoplastic disorders; lymphocyte
	88261	Chromosome analysis: count 5 cells, 1 karyotype, with banding
	88262	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding
	88280	Chromosome analysis; additional karyotypes, each study
	88291	Cytogenetics and molecular cytogenetics, interpretation, and report
Y-chromosome microdeletion testing	81403	Molecular pathology procedure, Level 4 (e.g., analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
Preimplantation-A (PGT-A)	81229	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [CGH] microarray analysis
	81479	Unlisted molecular pathology procedure
	89290	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); less than or equal to 5 embryos
	89291	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); greater than 5 embryos

Preimplantation-M (PGT-M)	89290	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); less than or equal to 5 embryos
	89291	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); greater than 5 embryos
	81479	Unlisted molecular pathology procedure
Preimplantation-SR (PGT-SR)	81228	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [CGH] microarray analysis
	81229	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis
	81479	Unlisted molecular pathology procedure
	89290	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); less than or equal to 5 embryos
	89291	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); greater than 5 embryos
Hormone level tests:		
Anti-mullerian hormone (AMH)	82166	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
	83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
Estradiol	82670	Estradiol; total
	82681	Estradiol; free, direct measurement (e.g., equilibrium dialysis)
Follicle stimulating hormone (FSH)	83001	Gonadotropin; follicle stimulating hormone (FSH)
Luteinizing hormone (LH)	83002	Gonadotropin; luteinizing hormone (LH)
Progesterone	84144	Progesterone
	83498	Hydroxyprogesterone, 17-d

Prolactin	84146	Prolactin
Testosterone (total and free)	84402	Testosterone; free
	84403	Testosterone; total
Thyroid stimulating hormone (TSH)	84443	Thyroid stimulating hormone (TSH)
Laboratory panels	80418	Combined rapid anterior pituitary evaluation panel This panel must include the following: Adrenocorticotrophic hormone (ACTH) (82024 x 4) Luteinizing hormone (LH) (83002 x 4) Follicle stimulating hormone (FSH) (83001 x 4) Prolactin (84146 x 4) Human growth hormone (HGH) (83003 x 4) Cortisol (82533 x 4) Thyroid stimulating hormone (TSH) (84443 x 4)
	80426	Gonadotropin releasing hormone stimulation panel This panel must include the following: Follicle stimulating hormone (FSH) (83001 x 4) Luteinizing hormone (LH) (83002 x 4)
Hysterosalpingogram (HSG)	58340	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography
	74740	Hysterosalpingography, radiological supervision and interpretation
	76831	Saline infusion sonohysterography (SIS), including color flow Doppler, when performed
Diagnostic hysteroscopy	58555	Hysteroscopy, diagnostic (separate procedure)
Diagnostic laparoscopy with or without chromotubation	58345	Transcervical introduction of fallopian tube catheter for diagnosis and/or re-establishing patency (any method), with or without hysterosalpingography
	58350	Chromotubation of oviduct, including materials
	74742	Transcervical catheterization of fallopian tube, radiological supervision and interpretation
Leukocyte count in semen	89325	Sperm antibodies
	53655	Antisperm antibodies test (immunobead)
Pelvic ultrasound (transabdominal or transvaginal)	76830	Ultrasound, transvaginal
	76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete

	76857	Ultrasound, pelvic (nonobstetric), real time with image documentation; limited or follow-up (e.g., for follicles)
Post ejaculatory urinalysis	89331	Sperm evaluation, for retrograde ejaculation, urine (sperm concentration, motility, and morphology, as indicated)

Scrotal, testicular, or transrectal ultrasound	76870	Ultrasound, scrotum and contents
	76872	Ultrasound, transrectal;
Semen analysis	89260	Sperm isolation; simple prep (e.g., sperm wash and swim-up) for insemination or diagnosis with semen analysis
	89261	Sperm isolation; complex prep (e.g., Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis
	89310	Semen analysis: motility and count (not including Huhner test)
	89320	Semen analysis; volume, count, motility, and differential
	89321	Semen analysis: sperm presence and motility of sperm, if performed
	89322	Semen analysis; volume, count, motility, and differential using strict morphologic criteria (e.g., Kruger)
	G0027	Semen analysis; presence and/or motility of sperm excluding Huhner
Sonohysterogram or saline infusion ultrasound	58340	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography
	76831	Saline infusion sonohysterography (SIS), including color flow Doppler, when performed
Testicular biopsy	54500	Biopsy of testis, needle (separate procedure)
	54505	Biopsy of testis, incisional (separate procedure)
Vasography	74440	Vasography, vesiculography, or epididymography, radiological supervision and interpretation
Treatment		
Artificial Insemination:		

Intravaginal insemination	58999	Unlisted procedure, female genital system (nonobstetrical)
Intracervical insemination	58321	Artificial insemination; intracervical
Intrauterine insemination	58322	Artificial insemination; intra-uterine
Sperm washing	58323	Sperm washing for artificial insemination
Case Rates	S4035	Stimulated intrauterine insemination (IUI), case rate
	S4042	Management of ovulation induction (interpretation of diagnostic tests and studies, nonface-to-face medical management of the patient), per cycle

Iatrogenic Infertility (Fertility Preservation)		
Collection of sperm	S4030	Sperm procurement and cryopreservation services; initial visit
	S4031	Sperm procurement and cryopreservation services; subsequent visit
	89264	Sperm identification from testis tissue
	55899	Unlisted Procedure, Male Genital System
Cryopreservation of sperm	S4030	Sperm procurement and cryopreservation services; initial visit
	S4031	Sperm procurement and cryopreservation services; subsequent visit
	89259	Cryopreservation; sperm
Ovarian stimulation,	S4042	Management of ovulation induction (interpretation of diagnostic tests and studies, nonface-to-face medical management of the patient), per cycle
Retrieval of eggs,	58970	Follicle puncture for oocyte retrieval, any method
	89254	Oocyte identification from follicular fluid
	76948	Echo guide ova aspiration
Fertilization	S4011	In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
	89268	Insemination of oocytes

	89280	Assisted oocyte fertilization, micro technique; less than or equal to 10 oocytes
	89281	Assisted oocyte fertilization, micro technique; greater than 10 oocytes
Oocyte cryopreservation	89337	Cryopreservation, mature oocyte(s)
Embryo cryopreservation	89258	Cryopreservation; embryo(s)
Storage	89342	Storage (per year); embryo(s)
	89343	Storage (per year); sperm/semen
	89346	Storage (per year); oocyte(s)
	S4027	Storage of previously frozen embryos
	S4040	Monitoring and storage of cryopreserved embryos, per 30 days
Embryo culture	89250	Culture of oocyte(s)/embryo(s), less than 4 days

	89272	Extended culture of oocyte(s)/embryo(s), 4 -7 days
Assisted Reproductive Technology		
Embryo transfer	89255	Preparation of embryo for transfer (any method)
	58974	Embryo transfer, intrauterine
	58976	Gamete, zygote, or embryo intrafallopian transfer, any method
	S4037	Cryopreserved embryo transfer, case rate
Gamete intrafallopian transfer (GIFT)	S4013	Complete cycle, gamete intrafallopian transfer (GIFT), case rate
	58976	Gamete, zygote, or embryo intrafallopian transfer, any method
Zygote intrafallopian transfer (ZIFT)	S4014	Complete cycle, zygote intrafallopian transfer (ZIFT), case rate
	58976	Gamete, zygote, or embryo intrafallopian transfer, any method
In Vitro Fertilization (IVF)	S4011	In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
	S4015	Complete in vitro fertilization cycle, not otherwise specified, case rate

	S4017	Incomplete cycle, treatment cancelled prior to stimulation, case rate
	S4020	In vitro fertilization procedure cancelled before aspiration, case rate
	S4021	In vitro fertilization procedure cancelled after aspiration, case rate
	S4022	Assisted oocyte fertilization, case rate
	89268	Insemination of oocytes
	89280	Assisted oocyte fertilization, micro technique; less than or equal to 10 oocytes
	89281	Assisted oocyte fertilization, micro technique; greater than 10 oocytes
	S4016	Frozen in vitro fertilization cycle, case rate
	S4018	Frozen embryo transfer procedure cancelled before transfer, case rate
Cost of donor egg	S4023	Donor egg cycle, incomplete, case rate

	S4025	Donor services for in vitro fertilization (sperm or embryo), case rate
Cost of donor sperm	S4026	Procurement of donor sperm from sperm bank
Fertility drugs	S0126	Injection, follitropin alfa, 75 IU
	S0128	Injection, follitropin beta, 75 IU
	S0122	Injection, menotropins, 75 IU
	J9202	Goserelin acetate implant, per 3.6 mg
	S0132	Injection, ganirelix acetate, 250 mcg
	J3355	Injection, urofollitropin, 75 IU
	J0725	Injection, chorionic gonadotropin, per 1,000 USP units
	J9217	Leuprolide acetate (for depot suspension) 7.5 mg
	J9218	Leuprolide acetate, per 1 mg
	J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg
	J1951	Injection, leuprolide acetate for depot suspension (Fensolvi), 0.25 mg
	J1952	Leuprolide injectable, camcevi, 1 mg
	J1954	Injection, leuprolide acetate for depot suspension (Cipla), 7.5 mg
	J1050	Injection, medroxyprogesterone acetate, 1 mg.
	J2675	Injection, progesterone, per 50 mg

	J1380	Injection, estradiol valerate, up to 10 mg
Genetic counseling	96040	Genetic counseling 30 min
	S0265	Genetic counseling, under physician supervision, each 15 minutes
Infertility services after voluntary sterilizations	Z98.51 Z98.52 Z31.0	Tubal ligation status Vasectomy status Encounter for reversal of previous sterilization
	S4028	Microsurgical epididymal sperm aspiration (mesa)
	89257	Sperm identification from epididymal or vasal fluid
Preimplantation diagnosis, testing, and/or screening of eggs, sperm, or embryos	89290	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); less than or equal to 5 embryos
	89291	Biopsy, oocyte polar body or embryo blastomere, micro technique (for preimplantation genetic diagnosis); greater than 5 embryos

	0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy, per embryo tested
Reversal of voluntary surgical sterilizations	55400	Vasovasostomy (unilateral or bilateral)
	58750	Tubotubal anastomosis
	58752	Tubouterine implantation
	58760	Fimbrioplasty
	58770	Salpingostomy (salpingoneostomy)
Services and supplies related to ART procedures	89253	Assisted hatching
	89255	Prepare embryo for transfer
	89352	Thawing of cryopreserved; embryo(s)
	89353	Thawing of cryopreserved; sperm/semens, each aliquot
	89356	Thawing of cryopreserved; oocytes, each aliquot
	89250	Culture of oocyte(s)/embryo(s), less than 4 days

	89272	Extended culture of oocyte(s)/embryo(s), 4 -7 days
Unproven/ not medically necessary		
Co-culture of embryos	89251	Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos
Cryopreservation of immature oocytes, ovarian tissue, or testicular tissue	89335	Cryopreservation, reproductive tissue, testicular
	89344	Storage (per year); reproductive tissue, testicular/ovarian
	89354	Thawing of cryopreserved; reproductive tissue, testicular/ovarian
	89398	Unlisted reproductive medicine laboratory procedure (includes cryopreservation immature oocytes; ovarian reproductive tissues)
	0357T	Cryopreservation; immature oocyte(s)
EmbryoGlue	89398	Unlisted reproductive medicine laboratory procedure
Hyaluronan binding assay (HBA)	89398	Unlisted reproductive medicine laboratory procedure; includes Hyaluronan binding assay (HBA)

	0087T	Sperm evaluation, Hyaluronan sperm binding test
In vitro maturation (IVM) of oocytes	89398	Unlisted reproductive medicine laboratory procedure
Inhibin B	83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
Post-coital cervical mucus penetration test	89300	Semen analysis; presence and/or motility of sperm including Huhner test (post coital)
	Q0115	Postcoital direct, qualitative examinations of vaginal or cervical mucous
Reactive oxygen species (ROS) testing	82542	Column chromatography, includes mass spectrometry, if performed (e.g., HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
	89240	Unlisted miscellaneous pathology test
Sperm Acrosome reaction test	89398	Unlisted reproductive medicine laboratory procedure

	88346	Immunofluorescence, per specimen; initial single antibody stain procedure
Sperm capacitation test	89240	Unlisted miscellaneous pathology test
	0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score
Sperm DNA integrity/fragmentation test	89240	Unlisted miscellaneous pathology test
Sperm penetration assays	89329	Sperm evaluation; hamster penetration test
	89330	Sperm evaluation; cervical mucus penetration test, with or without spinnbarkeit test
Uterine/endometrial receptivity testing	0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (e.g., pre-receptive, receptive, postreceptive)
Treatments to improve uterine/endometrial receptivity		
	97810	Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
	97811	Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)
	97813	Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
	97814	Acupuncture, 1 or more needles; with electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)

Scientific References

Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services, National Guideline Clearinghouse | Fertility: assessment and treatment for people with fertility problems. [http://guideline.gov/content.aspx?f=rss&id=43841&osrc=12\[5/20/2013 9:54:47 AM\]](http://guideline.gov/content.aspx?f=rss&id=43841&osrc=12[5/20/2013 9:54:47 AM])

Agency for healthcare research and quality (AHRQ), U.S. Department of Health and Human Services, National Guideline Clearinghouse Comparative Effectiveness Review Number 217 Management of Infertility. AHRQ Publication No. 19-EHC014-EF May 2019.

Alasmari NM, Son WY, Dahan MH. The effect on pregnancy and multiples of transferring 1-3 embryos in women at least 40 years old. *J Assist Reprod Genet* 2016;33:1195-202.

Albrozi S, Motazedian S, Parsanezhad M, et al. Comparison of the effectiveness of single intrauterine insemination (IUI) versus double IUI per cycle in infertile patients. *Fertil Steril* 2003. 80:595-99.

Alvarez JP, Akopians AI, Wang ET, et al. Outcomes of utilized autologous cryopreserved oocytes. *Fertil Steril* 2015; 104:e267-8.

Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al, Poseidon Group (Patient Oriented Strategies Encompassing Individualized Oocyte Number). A new more detailed stratification of low responder to ovarian stimulation: from a poor ovarian response to a low prognosis concept. *Fertil Steril* 2016;105:1452–3.

Practice Committee of the American Society for Reproductive Medicine and the Practice Committee for the Society for Assisted Reproductive Technologies. Guidance on the limits to the number of embryos to transfer: a committee opinion. *Fertil Steril*. 2021 Sep;116(3):651-654.

Arab S, Badegiesh A, Aldaheri S, et al. What are the live birth and multiple pregnancy rates when 1 versus 2 low-quality blastocysts are transferred in a cryopreserved cycle? A retrospective cohort study, stratified for age, embryo quality, and oocyte donor cycles. *Reproductive Sciences*. 2021 May;28(5):1403-1411. doi: 10.1007/s43032-020-00404-2. Epub 2020 Nov 25. PMID: 33237513.

ASRM. The Practice Committee of the American Society for Reproductive Medicine: Guidance on the limits to the number of embryos to transfer: a committee opinion. *Fertil Steril* 2021;116:651-54.

ASRM. The Practice Committee of the American Society for Reproductive Medicine: Definitions of infertility and recurrent pregnancy loss. *Fertil Steril* 2020;113:533-5.

ASRM. The Practice Committee of the American Society for Reproductive Medicine: Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion. *Fertil Steril* 2020;114:239-45.

ASRM Practice Committee Guideline: Evidence based treatments for couples with unexplained infertility: a guideline. *Fertil Steril* 2020;113:305-22.

ASRM The Ethics Committee of the American Society for Reproductive Medicine. Fertility Treatment When the Prognosis is Very Poor or Futile: a Committee Opinion. *Fertil Steril* 2019;111:659-63.

American Society for Reproductive Medicine (ASRM). Infertility. [https://www.reproductivefacts.org/news-and-publications/factsheets-and-infographics/diagnostictesting-for-female-infertility/American Society for Reproductive Medicine](https://www.reproductivefacts.org/news-and-publications/factsheets-and-infographics/diagnostictesting-for-female-infertility/American-Society-for-Reproductive-Medicine).

Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline. *Fertil Steril*. 2021d Jul;116(1):36-47.

ASRM (d). The Ethics Committee of the American Society for Reproductive Medicine. Oocyte or embryo donation to women of advanced reproductive age: an ethics committee opinion. *Fertil Steril* 2016;106:e3-e7.

ASRM Mature Oocyte Cryopreservation: A guideline. *Fertil Steril* 2013;99:37-43.

ASRM. The Practice Committee of the American Society for Reproductive Medicine: Testing and interpreting measures of ovarian reserve. *Fertil Steril* 2020;114:1151–7.

ASRM Ethics Committee of the American Society for Reproductive Medicine. Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion. *Fertil Steril* 2019;111:659–63. 2.

American Society for Reproductive Medicine (ASRM) Practice Committee of the American Society for Reproductive Medicine. Female age-related fertility decline. (*Fertil Steril* 2014;101:633–4.

American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. *Fertil Steril*. 2021b Feb;115(2):298-304.

American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. *Fertil Steril*. 2021c Nov;116(5):1255-1265. American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. *Fertil Steril*. 2021b Feb;115(2):298-304.

American Society for Reproductive Medicine. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertil Steril*. 2020c Dec;114(6):1151-1157.

American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. *Fertil Steril*. 2019c Dec;112(6):1022-1033.

American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. *Fertil Steril*. 2018a Aug;110(3):380-386.

Ata B, Abou-Setta AM, Seyhan A, Buckett W. Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer). *Cochrane Database Syst Rev* 2018;2:CD011809.

Ayeleke RO, Asseler JD, Cohlen BJ, et al. Intra-uterine insemination for unexplained subfertility. *The Cochrane database of systematic reviews* 2020;3:CD001838.

Baart E, Martini E, Eijkemans M, et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. *Human Reprod* 2007 Apr; 22(4): 980-8.

Balaban B, Urman B, Sertac A, Alatas C, Aksoy S, Mercan R. Blastocyst quality affects the success of blastocyst-stage embryo transfer. *Fertil Steril* 2000;74:282–7

Bhattacharya S, Hamilton MP, Shaaban M, Khalaf Y, Seddler M, et al. Conventional in-vitro fertilization versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial. *Lancet* 2001;357:2075–9

Benadiva CA, Nulsen J, Siano L, Jennings J, Givargis HB, Maier D. Intracytoplasmic sperm injection overcomes previous fertilization failure with conventional in vitro fertilization. *Fertil Steril* 1999;72:1041–4

Bernie AM, et al. Microsurgical epididymal sperm aspiration: indications, techniques and outcomes. *Asian J Androl.*, 2013;15(1;40-43).

Blake DA, Farquhar CM, Johnson N, et al. Cleavage stage versus blastocyst stage embryo transfer in assisted conception. *Cochrane Database Syst Rev* 2007;4:CD002118.

Brigham SA , Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. *Hum Reprod*1999;14:2868–2871.

Busnelli A, Somigliana E, Cirillo F, et al. Efficacy of therapies and interventions for repeated embryo implantation failure: a systematic review and meta-analysis. *Sci Rep.* 2021;11:1747.

Busnelli A, Dallagiovanna C, Reschini M, et al. Risk factors for monozygotic twinning after in vitro fertilization: a systematic review and meta-analysis. *Fertility and Sterility.* 2019;111:302-317.

Carles, M. et.al. In vitro maturation of oocytes from stimulated IVF-ICSI cycles using autologous cumulus cell co-culture: A preliminary study *Morphologie.* 2023 Mar;107(356):28-37. doi: 10.1016/j.morpho.2022.02.002. Epub 2022 Jun 25.

Carosso AR, van Eekelen R, Revelli A, et al. Expectant Management Before In vitro Fertilization in Women Aged 39 or Above and Unexplained Infertility Does Not Decrease Live Birth Rates Compared to Immediate Treatment. *Reproductive sciences (Thousand Oaks, Calif)* 2022;29:1232-1240.

Cayan S, Lee D, Conaghan J, Givens CA, Ryan IP, et al. A comparison of ICSI outcomes with fresh and cryopreserved epididymal spermatozoa from the same couples. *Hum Reprod.* 2001;16:495-9.

Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. *Int J Transgender Health.* 2022;23(sup1):S1-S259.

Cooper TG, Noonan E, von Eckerdstein S, et al. M: World Health Organization reference values for human sperm characteristics. *Human Reprod Update* 2010; 16: 231-245.

Criniti A, Thyer A, Chow G, Lin P, Klein N, Soules M. Elective single blastocyst transfer reduces twin rates without compromising pregnancy rates. *Fertil Steril.* 2005;84:1613–1619.

Csokmay JM, Hill MJ, Chasin RJ et al. Experience with a patient-friendly, mandatory, single-blastocyst transfer policy: the power of one. *Fertil Steril* 2011;96:580–4.

Danhof NA, Wang R, van Wely M, van der Veen F, Mol BWJ, Mochtar MH. IUI for unexplained infertility: a network meta-analysis. *Hum Reprod Update* 2020;26:1–15

Dare MR, Crowther CA, Dodd JM et al. Single or multiple embryo transfer following in vitro fertilization for improved neonatal outcome: A systematic review of the literature. *Aust NZ J Obstet Gynaecol* 2004; 44: 283- 291.

Davis LB, Lathi RB, Westphal LM, Milki AA. Elective single blastocyst transfer in women older than 35. *Fertil Steril* 2008;89:230–1.

Deutsch MB. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd Edition. UCSF Center of Excellence for Transgender Health. Published June 17, 2016. Accessed January 31, 2023. <https://transcare.ucsf.edu/guidelines>

Devine S, Connell MT, Richter KS, et al. Single vitrified blastocyst transfer maximizes liveborn children per embryo while minimizing preterm birth. *Fertil Steril*. 2015 Jun;103(6):1454–60.

Devesa M, Tur R, Rodriguez I, Coroleu B, Martinez F, Polyzos NP. Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women R38 years old. *Hum Reprod* 2018;33:2010–7.

Dickey RP, Taylor SN, Lu PY, et al. The number of cycles of gonadotropin-intrauterine insemination should be tailored to follicular response. *Fertil Steril* 2003; 80: S213.

Doody KJ. Cryopreservation and delayed embryo transfer-assisted reproductive technology registry and reporting implications. *Fertil Steril* 2014; 102:27–31

Estudillo E, Jiménez A, Bustamante-Nieves PE, Palacios-Reyes C, Velasco I, López-Ornelas A. Cryopreservation of Gametes and Embryos and Their Molecular Changes. *Int J Mol Sci*. 2021 Oct 8;22(19):10864. doi: 10.3390/ijms221910864. PMID: 34639209; PMCID: PMC8509660.

Ethics Committee of the American Society for Reproductive Medicine. Access to fertility services by transgender and nonbinary persons: an Ethics Committee opinion. *Fertil Steril*. 2021;115(4):874-878.

European Society of Human Reproduction and Embryology (ESHRE) Guideline: Number of embryos to transfer during IVF/ICSI. The ESHRE guideline group on the number of embryos to transfer during IVF/ICSI. Alteri A, Arroyo G, Baccino G, et al. Evidence-based guideline: Number of embryos to transfer during IVF/ICSI. 2024. Available at: <https://doi.org/10.1093/humrep/deae010>.

Farquhar CM, Liu E, Armstrong S, et al. Intrauterine insemination with ovarian stimulation vs. expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, twocentre trial. *Lancet* 2018;391:441-50.

Fauque P, Jouannet P, Davy C, Guibert J, et al. Cumulative results including obstetrical and neonatal outcome of fresh and frozen-thawed cycles in elective single versus double fresh embryo transfers. *Fertil Steril* 2010;94:927-935.

Fausser BC, Nargund G, Anderson AN, et al. Mild ovarian stimulation for IVF: 10 years later. *Human Reprod*. 2010 Nov; 25(11): 2678-84.

Finelli, R. et. al. The validity and reliability of computer-aided semen analyzers in performing semen analysis: a systematic review. *Translational Andrology and Urology*. 2021 Jul; 10(7): 3069–3079. doi: 10.21037/tau-21-276

Foong SC, Fleetham JA, O'Keane JA, Scott SG, Tough SC, Greene CA. A prospective randomized trial of conventional in vitro fertilization versus intracytoplasmic sperm injection in unexplained infertility. *J Assist Reprod Genet* 2006;23:137–40.

Forman EJ, Hong KH, Ferry KM, et al. In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. *Fertil Steril* 2013; 100: 100-7.

Franasiak JM, Forman EJ, Hong KH, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophoctoderm biopsies evaluated with comprehensive chromosomal screening. *Fertil Steril* 2014;101:656–63.e1.

Fuat, K. & Baris, A. Sperm function tests in clinical practice. *Turk J Urol*. 2017 Dec; 43(4): 393–400. Published online 2017 Dec 1. doi: 10.5152/tud.2017.96646

Fujimoto A, Morishima K, Harada M, et al. Elective single-embryo transfer improves cumulative pregnancy outcome in young patients but not in women of advanced reproductive age. *J Assist Reprod Genet*. 2015 Dec;32(12):1773–1779.

Gardner DK, Surrey E, Minjarez D, Leitz A, Stevens J, Schoolcraft WB. Single blastocyst transfer: a prospective randomized trial. *Fertil Steril* 2004;81: 551–5.

Geng T, Geng L, Ge C, Zhang T. The effect of ICSI in infertility couples with non-male factor: a systematic review and meta-analysis. *Journal of Assisted Reproduction and Genetics* (2020) 37:2929–2945.

Gerber R, Fazzari M, Kappy M, et al. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study. *Fertil Steril* 2020; 114: 1225-1231.

Glujovsky D, Quinteiro Retamar AM, Alvarez Sedo CR, et al. Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology. *The Cochrane database of systematic reviews*. 2022;5:Cd002118.

Goldman MB, Thornton KL, Ryley D, Alper MM, Fung JL, Hornstein MD, et al. A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). *Fertil Steril* 2014;101:1574-81.e1-2.

Gordon J, DiMattina M, Reh A, et al. Utilization and success rates of unstimulated in vitro fertilization in the United States: an analysis of the Society for Assisted Reproductive Technology database. *Fertil Steril* 2013; 100:392-395.

Grady R, Alavi N, Vale R et al. Elective single embryo transfer and perinatal outcomes: a systematic review and meta-analysis. *Fertil Steril* 2012;97:324–31.

Griffo J, Hodes-Wertz B, Lee H-L. Single thawed euploid embryo transfer improves IVF pregnancy, miscarriage, and multiple gestation outcomes and has similar implantation rates as egg donation. *J Assist Reprod Genet*. 2013 Feb;30(2):259-64.

Sarah Harris, Dallas Reed, Neeta L. Vora, Screening for fetal chromosomal and subchromosomal disorders, *Seminars in Fetal and Neonatal Medicine*, Volume 23, Issue 2, 2018, Pages 85-93, ISSN 1744165X.

Hayes Health Technology Assessment. Ovarian Tissue Cryopreservation for Preservation of Fertility in Patients Undergoing Gonadotoxic Cancer Treatment. Nov 2021.

<https://evidence.hayesinc.com/report/htb.ovarian3754>

Helmerhorst FM, Van Vliet HA, Gornas T, et al. Intra-uterine insemination versus timed intercourse or expectant management for cervical hostility in subfertile couples. *Cochrane Database Syst Rev.* 2005 Oct 9;(4):CD002809.

Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2017;102(11):3869-3903.

Henman M, Catt JW, Wood T, et al. Elective transfer of single fresh blastocysts and later transfer of cryostored blastocysts reduces the twin pregnancy rate and can improve the in vitro fertilization live birth rate in younger women. *Fertil Steril* 2005;84:1620–7.

Hershlag A, Paine T, Cooper GW, Scholl GM, Rawlinson K, Kvapil G. Monozygotic twinning associated with mechanical assisted hatching. *Fertil Steril* 1999;71:144–6.

Hill MJ, Richter KS, Heitmann RJ et al. Number of supernumerary vitrified blastocysts is positively correlated with implantation and live birth in single-blastocyst embryo transfers. *Fertil Steril* 2013;99:1631–6.

Hill MJ, Eubanks AE, Csokmay JM, et al. Is transferring a lower-quality embryo with a good-quality blastocyst Detrimental to the likelihood of live birth? *Fertility and Sterility.* 2020;114:338-345.

van Hoogenhuijze NE, Mol F, Laven JSE et al. Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH). *Hum Reprod.* 2021 Jan 1;36(1):87-98.

Hourvitz A, Machtinger R, Maman E, Baum M, Dor J, Levron J. Assisted reproduction in women over 40 years of age: how old is too old? *Reprod Biomed Online* 2009;19:599–603.

Intracytoplasmic sperm injection (ICSI) in 2006: evidence and evolution. *Hum Reprod Update* 2007;13:515–26.

Ishihara O, Araki R, Kuwahara A, Itakura A, Saito H, Adamson GD. Impact of frozen-thawed singleblastocyst transfer on maternal and neonatal outcome: an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. *Fertil Steril* 2014;101:128–33.

Jaffe T, Oates RD. Genetic abnormalities and reproductive failure. In: Lipshultz LI, ed. *Urologic clinics of North America.* Philadelphia: W.B. Saunders Company, 1994.

Johnson LNC, Sasson IE, Sammel MD and Dokras A: Does intracytoplasmic sperm injection (ICSI) improve the fertilization rate and decrease the total fertilization failure rate in couples with well-defined unexplained infertility? *Fertil Steril* 2012;98:S286.

Kalra SK, Ratcliffe SJ, Coutifaris C, Molinaro T, Barnhart KT. Ovarian stimulation and low birth weight in newborns conceived through in vitro fertilization. *Obstet Gynecol* 2011;118:863–71.

Kamath MS, Mascarenhas M, Franik S, et al. Clinical adjuncts in in vitro fertilization: a growing list. *Fertil Steril* 2019;112:978-86.

Kamath MS, Mascarenhas M, Kirubabkarn R, et al. Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection. The Cochrane database of systematic reviews. 2020;8:Cd003416.

Kasaven LS, Marcus D Theodorou E, et al. Systematic review and meta-analysis: does pre-implantation genetic testing for aneuploidy at the blastocyst stage improve live birth rate? Journal of Assisted Reproduction and Genetics. 2023;40:2297-2316.

Kastrop PM, Weima SM, Van Kooij RJ, Te Velde ER. Comparison between intracytoplasmic sperm injection and in-vitro fertilization (IVF) with high insemination concentration after total fertilization failure in a previous IVF attempt. Hum Reprod 1999;14:65–9.

Kato K, Takehara Y, Segawa T et al. Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-centre, Japanese cohort. Reproductive Biology and Endocrinology 2012,10:35.

Kattal N, Cohen J, Barmat LI. Role of coculture in human in vitro fertilization: a meta-analysis. Fertil Steril. 2008 Oct;90(4):1069-76.

Kim HH, Bundorf MK, Behr B, McCallum SW. Use and outcomes of intracytoplasmic sperm injection for nonmale factor infertility. Fertil Steril 2007;88:622–8.

Kirby CA, Flaherty SP, Godfrey BM, Warnes GM, Matthews CD. A prospective trial of intrauterine insemination of motile spermatozoa versus timed intercourse. Fertil Steril 1991;56:102-7.

Klipstein S, Regan M, Ryley DA, Goldman MB, Alper MM, Reindollar RH. One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above. Fertil Steril 2005;84:435– 45. 9.

Ko, Edmund S. Sabanegh, Ashok Agarwal. Male infertility testing: reactive oxygen species and antioxidant capacity. Fertility and Sterility, Volume 102, Issue 6, 2014, Pages 1518-1527.
<https://doi.org/10.1016/j.fertnstert.2014.10.020>.

Kresowik J, Stegmann B, Sparks AE et al. Five-years of a mandatory single-embryo transfer (mSET) policy dramatically reduces twinning rate without lowering pregnancy rates. Fertil Steril 2011;96:1367–9.

Kushnir VA, Darmon SK, Albertini DF, et al. Effectiveness of in vitro fertilization with preimplantation genetic screening: a reanalysis of United States assisted reproductive technology data 2011-2012. Fertil Steril 2016;106:75–9.

LeFevre NM, Sundermeyer RL. Fetal Aneuploidy: Screening and Diagnostic Testing. Am Fam Physician. 2020 Apr 15;101(8):481-488. PMID: 32293844.

La Marca A, Kamal Sunkara SK: Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human Reprod 2014: 20, 124-140.

Lee HL, McCulloh DH, Hodes-Wertz B, et al. In vitro fertilization with preimplantation genetic screening improves implantation and live birth in women age 40 through 43. J Assist Reprod Genet 2015;32:435– 44.

Le Lannou D, Griveau JF, Laurent MC, et al. Contribution of embryo cryopreservation to elective single embryo transfer in IVF-ICSI. *Reprod Biomed Online* 2006;13:368–75.

LeSaint, C. et.al. Autologous endometrial cell co-culture improves human embryo development to high quality blastocysts: a randomized controlled trial. Jan 2019.

DOI:<https://doi.org/10.1016/j.rbmo.2018.12.039>

Lazarevic, J. et. al. Hyaluronan binding assay (HBA) vs. sperm penetration assay (SPA): Can HBA replace the SPA test in male partner screening before in vitro fertilization? *J Exp Clin Assist Reprod*. 2010; 7: 2. Published online 2010 Feb 10.

Li Z, Wang YA, Ledger W, Edgar DH, Sullivan EA. Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing: a population-based cohort study. *Hum Reprod* 2014;29:2794–801.

Liu KE, Case A. Advanced reproductive age and fertility. (No. 346). *Journal of Obstetrics and Gynaecology Canada* 2017;39(8):685-695. DOI: 10.1016/j.jogc.2016.12.004.

Liu Z, Lui X, Wang M et al. The clinical efficacy of personalized embryo transfer guided by the Endometrial Receptivity array/analysis on IVF/ICSI outcomes: A systematic review and meta-analysis. *Front Physiol* 2022; 13;841437.

Luna M, Bigelow C, Duke M, Ruman J, Sandler B, Grunfeld L, Copperman AB. Should ICSI be recommended routinely in patients with four or fewer oocytes retrieved? *J Assist Reprod Genet* 2011;28(10):911–5.

Lund M, Kamper-Jørgensen M, Nielsen HS, et al. Prognosis for live birth in women with recurrent miscarriage: what is the best measure of success? *Obstet Gynecol* 2012; 119:37–43.

Luna M, Grunfeld L, Mukherjee T, et al. Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response but should not be used to disqualify patients from attempting in vitro fertilization. *Fertil Steril* 2007;87:782–787.

Ma S, Peng Y, Hu L, et al. Comparisons of benefits and risks of single embryo transfer versus double embryo transfer: a systematic review and meta-analysis. *Reproductive Biology and Endocrinology*. 2022;20:20.

Maheshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. *Fertil Steril* 2012;98:368–377.e1-9.

McLernon DJ, Harrild K, Bergh C et al. Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials. *BMJ* 2010;341:c6945.

Mejia RB, Capper EA, Summers KM, et al. Elective transfer of one embryo is associated with a higher cumulative live birth rate and improved perinatal outcomes compared to the transfer of two embryos with in vitro fertilization. *F&S reports*. 2021;2:50-57.

Merchant R, Gandhi G, Allahbadia GN. In-Vitro Fertilization/Intracytoplasmic sperm injection for male infertility Deccan Fertility Clinic Rotunda-Center for Human Reproduction Mumbai India. *Indian Journal of Urology* Jan- Mar 2011;27:121-132.

Mersereau J, Stanhiser J, Coddington, C, et al. Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology outcomes between 2004 and 2013. *Fertility and Sterility*. 2017;108:750-756.

Merviel P, Heraud MH, Grenier N, et al. Predictive factors for pregnancy after intrauterine insemination (IUI): An analysis of 1038 cycles and a review of the literature. *Fertil Steril* 2010;93:79–88.

Mohit Khera, Larry I. Lipshultz, Chapter 54 - Male Infertility, Editor(s): Eric J. Bieber, Joseph S. Sanfilippo, Ira R. Horowitz. *Clinical Gynecology*. Churchill Livingstone. 2006. Pages 779-795, ISBN 9780443066917. <https://doi.org/10.1016/B978-0-443-06691-7.50059-5>.

Moody MA, Cardona C, Simpson AJ, et al Validation of a laboratory-developed test of human sperm capacitation. *Mol Reprod Dev*. 2017; 84(5):408-422.

Mullin CM, Fino ME, Talebjan S et al. Comparison of pregnancy outcomes in elective single blastocyst transfer versus double blastocyst transfer stratified by age. *Fertility and Sterility* 2010; 93: 1837-1843.

Mullin C, Berkeley AS, Grifo JA. Supernumerary blastocyst cryopreservation: a key prognostic indicator for patients opting for an elective single blastocyst transfer (eSBT). *J Assist Reprod Genet* 2012;29:783– 8.

Murugappan G, Ohno MS, Lathi RB. Cost-effectiveness analysis of preimplantation genetic screening and in vitro fertilization versus expectant management in patients with unexplained recurrent pregnancy loss. *Fertil Steril* 2015;103:1215–20.

Nakashima A, Araki R, Tani H, Ishihara O, Kuwahara A, Irahara M, et al. Implications of assisted reproductive technologies on term singleton birth weight: an analysis of 25,777 children in the national assisted reproduction registry of Japan. *Fertil Steril* 2013;99:450–5.

Nardo LG, Gelbaya TA, Wilkinson H, et al. Circulating basal anti Müllerian hormone levels as predictor of ovarian response in females undergoing ovarian stimulation for in vitro fertilization. *Fertil Steril* 2009;92:1586-1593.

Nargund G, Datta AK and Fauser BCJM. Mild Stimulation for in vitro fertilization. *Fertil Steril* 2017;108: 558-67.

Niinimäki M, Suikkari AM, Mäkinen S et al. Elective single-embryo transfer in women aged 40–44 years. *Human Reproduction* 2013;28:331–335. NLM. National Library of Medicine, <http://www.nlm.nih.gov/medlineplus/ency/article/003710.htm>.

Nicopoulos JD and Abdalla H. Poor response cycles: when should we cancel? Comparison of outcome between egg collection, intrauterine insemination conversion, and follow-up cycles after abandonment. *Fertil Steril* 2011;95:68–71.

Norian JM, Levens ED, Richter KS, et al. Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? *Fertil Steril* 2010; 94:2073-7.

Oktaç K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol*. 2018;36(19):1994-2001.

Osuna C, Matorras R, Pijoin IJ, et al. One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature. *Fertil Steril* 2004; 82:17-24.

Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet* 1999;340:17–8.

Pandian Z, Gibreel A, Bhattacharya S. In vitro fertilisation for unexplained subfertility. *The Cochrane database of systematic reviews* 2015;2015: Cd003357.

Pandian Z, Marjoribanks J, Ozturk O, et al. Number of embryos for transfer following in vitro fertilization or intracytoplasmic sperm injection: summary of a Cochrane review. *Fertil Steril*. 2014 Aug;102(2):345–7.

Pandian Z, Bhattacharya S, Ozturk O, Serour G, Templeton A. Number of embryos for transfer following in-vitro fertilization or intra-cytoplasmic sperm injection. *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD003416. DOI: 10.1002/14651858.CD003416.pub3.

Papanikolaou EG, Camus D, Kolibianakis EM, et al. In vitro fertilization with single blastocyst-stage versus cleavage-stage embryos. *N Engl J Med*. 2006;354:1139–1146.

Papanikolaou EG, Kolibianakis EM, Tournaye H, et al. Live birth rates after transfer of equal number of blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysis. *Hum Reprod* 2008;23:91–99.

Peigne M, de Mouzon J, Khiel A, Fraissinet A, et al. Donated-embryo pregnancies are associated with increased risk of hypertensive disorders even for young recipients: a retrospective matched-cohort study. *Fertility and Sterility*. 2023;119:69-77.

Polyzos N, Blockeel C, Verpoest W, et al. Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria. *Hum Reprod* 2012;27S:30.

Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including 15,000 women. *Fertil Steril* 2018;110:661–70.e1

Practice Committee of the American Society for Reproductive Medicine: Elective single embryo transfer. *Fertil Steril* 2012;97:835–42.

Practice Committee of the American Society for Reproductive Medicine: Guidance on the limits of the number of embryos to transfer: a committee opinion. *Fertil Steril* 2021;116:651-54.

Practice Committee of the American Society for Reproductive Medicine, American Society for Reproductive Medicine: The role of assisted hatching in in vitro fertilization: a guideline *Fertil Steril* 2014;102:348–51.

Racca A, Drakopoulos P, Van Landuyt L, et al. Single and double embryo transfer provide similar live birth rates in frozen cycles. *Gynecological Endocrinology: the official journal of the International Society of Gynecological Endocrinology*. 2020;36:824-828.

Raga F, Bauset C, Remohi J, et al. Reproductive impact of congenital Mullerian anomalies. *Hum Reprod* 1997;12:2277–2281.

Reichman DE, Gunnala V, Meyer L, et al. In vitro fertilization versus conversion to intrauterine insemination in the setting of three or fewer follicles: how should patients proceed when follicular response falls short of expectation? *Fertil Steril* 2013;100:94–9.

Reilly DR. Surrogate pregnancy: a guide for Canadian prenatal health care providers. *CMAJ* 2007;176:483–485.

Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. *Fertil Steril* 2010;94:888–99.

Reindollar RH, Thornton KL, Ryley D, et al. A randomized clinical trial to determine optimal infertility therapy in couples when the female partner is 38-42 years: preliminary results from the forty and over infertility treatment trial (FORT-T). *Fertil Steril* 2011;96:S1.

Richter KS, Shipley SK, McVearry I, et al. Cryopreserved embryo transfers suggest that endometrial receptivity may contribute to reduced success rates of later developing embryos. *Fertil Steril* 2006;86:862–6.

Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. *Hum Reprod* 2012;27:1606–12.

Rodriguez-Wallberg KA, Berger AS, Fagerberg A, et al. Increased incidence of obstetric and perinatal complications in pregnancies achieved using donor oocytes and single embryo transfer in young and healthy women. A prospective hospital-based matched cohort study. *Gynecological Endocrinology: the official journal of the International Society of Gynecological Endocrinology*. 2019;35:314-319.

Rodriguez-Sallberg KA, Palomares AR, Milsson HP, et al. Obstetric and perinatal outcomes of singleton births following single- vs double-embryo transfer in Sweden. *JAMA Pediatrics*.2023;177:149-159.

Roest J, Van Heusden AM, Zeilmaker GH, Verhoeff A. Treatment policy after poor fertilization in the first IVF cycle. *J Assist Reprod Genet* 1998;15:18–21.

Romanski P, Bortoletto P, Malmstem J, et al. Pregnancy outcomes after oral and injectable ovulation induction in women with infertility with a low antimullerian hormone level compared with those with a normal antimullerian hormone level. *Fertil Steril* 2022;118:1048-56

Romao RL, Lorenzo AJ. Fertility preservation options for children and adolescents with cancer. *Can Urol Assoc J*. 2017 Jan-Feb;11(1-2Suppl1):S97-S102. doi: 10.5489/cuaj.4410. PMID: 28265333; PMCID: PMC5332250.

Roque M, Valle M, Guimaraes F, Sampaio M, Geber S. Cost-effectiveness of the freeze-all policy. *JBRA Assist Reprod* 2015a;19:125–130.

Rosen MP, Johnstone E, Addauan-Andersen C, et al. A lower antral follicle count is associated with infertility. *Fertil Steril* 2011; 95: 1950-52.

Ruiter-Ligeti J, Dahan M, Steiner N, et al. Is intrauterine insemination a viable treatment option for women over 43 years old? An analysis by ovarian stimulation protocol and sperm source. *Journal of Assisted Reproduction and Genetics* (2020) 37:3103–3107.

Russo ML, Blakemore KJ. A historical and practical review of first trimester aneuploidy screening. *Semin Fetal Neonatal Med.* 2014 Jun;19(3):183-7. doi: 10.1016/j.siny.2013.11.013. Epub 2013 Dec 14. PMID: 24333205; PMCID: PMC6596981.

Sahakyan M, Harlow BL, Hornstein MD. Influence of age, diagnosis, and cycle number on pregnancy rates with gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination. *Fertil Steril* 1999; 72: 500-504.

Salame Y, Devreker F, Imbert R et al. Contribution of cryopreservation in a mandatory SET policy: analysis of 5 years of application of law in an academic IVF center. *J Assist Reprod Genet* 2011; 28:1059–1066.

SART - Society for Assisted Reproductive Technology: National Clinic Summary, 2016. https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2016.

Schieve LA, Meikle SF, Peterson HB, Jeng G, Burnett NM, Wilcox LS. Does assisted hatching pose a risk for monozygotic twinning in pregnancies conceived through in vitro fertilization? *Fertil Steril* 2000;74:288–94.

Schimberni M, Morgia F, Colabianchi J, et al. Natural cycle in vitro fertilization in poor responder patients: a survey of 500 consecutive cycles *Fertil Steril* 2009; 92: 1297-1301.

Schlegel PN, Su LM. Physiologic consequences of testicular sperm extraction. *Hum Reprod* 1997;12:1688–92.

Schlegel PN. Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. *Hum Reprod* 1999;14:131-5.

Schlegel PN, Berkeley AS, Goldstein M, Cohen J, Alikani M, Adler A, et al. Epididymal micropuncture with in vitro fertilization and oocyte micromanipulation for the treatment of unreconstructable obstructive azoospermia. *Fertil Steril* 1994;61:895–901.

Schlegel PN, Sigman M, Collura B, Et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. *Fertil Steril* 2020; in press. Available at: <https://www.asrm.org/practiceguidance/practice-committeddocuments/diagnosis-and-treatment-of-infertility-in-men-uaa-asrmguideline-part1/>

Schlegel PN, Sigman M, Collura B, Et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. *Fertil Steril* 2020; in press. Available at:

<https://www.asrm.org/practiceguidance/practice-committeedocuments/diagnosis-and-treatment-of-infertility-in-men-aua-asrmguideline-part2/>

Schlegel P, Sigman M, Collura B et al. Diagnosis and Treatment of Infertility in Men: AUA/ ASRM Guideline part III. *Fertil Steril* 2020; in press

Schwarze JE, Crosby JA, Zegers-Hochschild F. Effect of embryo freezing on perinatal outcome after assisted reproduction techniques: lessons from the Latin American Registry of Assisted Reproduction. *Reprod Biomed Online* 2015;31:39–43.

Schwarzler P, Zech H, Auer M, Pfau K, Gobel G, Vanderzwalmen P, et al. Pregnancy outcome after blastocyst transfer as compared to early cleavage stage embryo transfer. *Hum Reprod.* 2004;19:2097–2102. Scott, RT. Diminished ovarian reserve and access to care. *Fertil Steril* 2004; 81:1489-1492.

Shapiro BS, Daneshmand ST, Garner FC, et al. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. *Fertil Steril* 2011;96:344–348.

Shapiro BS, Daneshmand ST, Restrepo H, et al. Matched-cohort comparison of single-embryo transfers in fresh and frozen-thawed embryo transfer cycles *Fertil Steril* 2013;99:389–92.

Shapiro BS, Harris DC, Richter KS. Predictive value of 72-hour blastomere cell number on blastocyst development and success of subsequent transfer based on the degree of blastocyst development. *Fertil Steril* 2000;73:582–6.

Shapiro BS, Richter KS, Harris DC, Daneshmand ST. Influence of patient age on the growth and transfer of blastocyst-stage embryos. *Fertil Steril* 2002;77:700–5.

Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Clinical rationale for cryopreservation of entire embryo cohorts in lieu of fresh transfer. *Fertil Steril* 2014a;102:3–9.

Shapiro BS, Daneshmand ST, Bedient CE, Gaarner FC. Comparison of birth weights in patients randomly assigned to fresh or frozen-thawed embryo transfer *Fertil Steril* 2016;106:317-21

Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Frozen embryo transfer following ‘Freeze All’ is a superior therapy to another fresh transfer in patients with prior fresh embryo implantation failure. *Fertil Steril* 2014b;101:e6.

Sheynkin YR, Ye Z, Menendez S, Liotta D, Veeck LL, Schlegel P. Controlled comparison of percutaneous and microsurgical sperm retrieval in men with obstructive azoospermia. *Hum Reprod* 1998;13:3086–9.

Silber S, Zsolt P, Liu NJ, et al. Conventional in-vitro fertilization versus intracytoplasmic sperm injection for patients requiring microsurgical sperm aspiration. *Human Reproduction.* 1994;9(9):1705-09.

Simon C, Vladimirov IK, Castillon Cortes G, et al. Prospective, randomized study of the endometrial receptivity analysis (ERA) test in the infertility work-up to guide personalized embryo transfer versus fresh transfer or deferred embryo transfer. *Fertil Steril* 2016;106: e46–7.

Simon C, Gomez C, Cabanillas S, Vladimirov IK, Castillon G, Giles J, et al. In vitro fertilization with personalized blastocyst transfer versus frozen or fresh blastocyst transfer: a multicenter, randomized clinical trial. *Fertil Steril* 2019;112:e56.

Society for Assisted Reproductive Technology: National Data Summary 2011. Available at: https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reporting year+2017.

Steiner AZ, Prtichard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. *JAMA* 2017; 318: 1367-1376

Styer AK, Wright DL, Wolkovich AM, Veiga C, Toth TL. Single-blastocyst transfer decreases twin gestation without affecting pregnancy outcome. *Fertil Steril* 2008;89:1702–8.

Sunderam S, Kissin DM, Flowers L et al. Assisted reproductive technology surveillance — United States, 2009. *MMWR Surveill Summ* 2012;61(7):1-23.

Takeshima K, Jwa SC, Saito H, et al. Impact of single embryo transfer policy on perinatal outcomes in fresh and frozen cycles—analysis of the Japanese Assisted Reproduction Technology registry between 2007 and 2012. *Fertil Steril* 2016 Feb;105(2):337–46.

Tannus S, Cohen Y, Son WY, et al. Cumulative live birth rate following elective single blastocyst transfer compared with double blastocyst transfer in women aged 40 years and over. *Reproductive Biomedicine online* 2017;35:733-738.

Taylor E, Gomel V. The uterus and fertility. *Fertil Steril* 2008; 89: 1-16. Theodorou E, Jones BP, Cawood S, et al. Adding a low-quality blastocyst to a high-quality blastocyst for a double embryo transfer does not decrease pregnancy and live birth rate. *Acta Obstetrica et Gynecologica Scandinavica*. 2021;100:11241131.

Thornhill AR, deDie-Smulders CE, Geraedts JP, Harper JC, Harton GL, et al. ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)’. *Hum Reprod* 2005;20:35–48.

Thurin A, Hausken J, Hillensjo T, Jablonowska B, Pinborg A, Strandell A, et al. Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. *N Engl J Med*. 2004;351:2392–2402.

Twaite A, Hall J, Barrett J, et al. How common is natural conception in women who have had a live birth via assisted reproductive technology? Systematic review and meta-analysis. *Human Reproduction*. 2023;38:1590- 1600.

Tonguc E, Var T, Onalan G, et al. Comparison of the effectiveness of single versus double intrauterine insemination with three different timing regimens. *Fertil Steril* 2010; 94: 1267-70.

Tournaye H, Devroey P, Liu J, Nagy Z, Lissens W, Van Steirteghem A. Microsurgical epididymal sperm aspiration and intracytoplasmic sperm injection: a new effective approach to infertility as a result of congenital absence of the vas deferens. *Fertil Steril* 1994;61:1045–51.

Tucker M, Graham J, Han T, Stillman R, Levy M. Conventional insemination versus intracytoplasmic sperm injection. *Lancet* 2001;358:1645–6.

Ubaldi F, Anniballo R, Romano S, Baroni E, Albricci L, Colamaria S, et al. Cumulative ongoing pregnancy rate achieved with oocyte vitrification and cleavage stage transfer without embryo selection in a standard infertility program. *Hum Reprod* 2010;25:1199–205.

Ubaldi FM, Capalbo A, Colamaria S, et al. Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo selection: pre- and post-intervention study. *Hum Reprod* 2015;30:2097–106.

Ubaldi FM, Cimadomo D, Capalbo A, Vaiarelli A, Buffo L, Trabucco E, et al. Preimplantation genetic diagnosis for aneuploidy testing in women older than 44 years: a multicenter experience. *Fertil Steril* 2017;107:1173–80.

Van der Westerlaken, Helmerhorst F, Dieben S, Naaktgeboren N. Intracytoplasmic sperm injection as treatment for unexplained total fertilization failure or low fertilization after conventional in vitro fertilization. *Fertil Steril* 2005;83:612–7.

Van Montfoort AP, Fiddelers AA, Janssen JM, Derhaag G, Dirksen C, Dunselman G, et al. In unselected patients, elective single embryo transfer prevents all multiples, but results in significantly lower pregnancy rates compared with double embryo transfer: a randomized controlled trial. *Hum Reprod* 2006;21:338–43.

Van Tilborg TC, Torrance HL, Oudshoorn SC, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. *Human Reprod* 2017; 32:2496-505.

Van Wely M, Barbey N, Meissner A, Repping S, Silber S. Live birth rates after MESA or TESE in men with obstructive azoospermia: is there a difference?, *Hum Reprod* 2015;30:761-766.

Vuong LN, Dang VQ, Ho TM, Huynh BG, Ha DT, Pham TD, et al. IVF transfer of fresh or frozen embryos in women without polycystic ovaries. *N Engl J Med* 2018;378:137–47.

Wasilewski T, Łukaszewicz-Zajac M, Wasilewska J, Mroczko B. Biochemistry of infertility. *Clin Chim Acta*. 2020 Sep;508:185-190. doi: 10.1016/j.cca.2020.05.039. Epub 2020 May 21. PMID: 32446954.

Wang S, Chen L, Fang J, et al. Comparison of the pregnancy and obstetric outcomes between single cleavagestage embryo transfer and single blastocyst transfer by time-lapse selection of embryos. *Gynecological Endocrinology: the official journal of the International Society of Gynecological Endocrinology*. 2019;35:792-795.

Weill Cornell Medicine. 2023 Endometrial Coculture. <https://ivf.org/treatments-and-services/advanced-ivf-techniques/endometrial-coculture>

Wennerholm UB, Henningsen AK, Romundstad LB, Bergh C, Pinborg A, Skjaerven R, et al. Perinatal outcomes of children born after frozen thawed embryo transfer: a Nordic cohort study from the CoNARTaS group. *Hum Reprod* 2013;28:2545–53.

Weinerman R, Mainigi M. Why we should transfer frozen instead of fresh embryos: the translational rationale. *Fertil Steril* 2014;102:10–18.

Whitney JB, Schiewe MC, Anderson RE. Single center validation of routine blastocyst biopsy implementation. *J Assist Reprod Genet* 2016;33:1507–13.

Wiser A, et al. Ovarian stimulation and intrauterine insemination in women aged 40 years or more. *Reproductive Biomedicine Online* 2012;24(2):170-3.

World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and SemenCervical Mucus Interaction. 4th ed. Cambridge: Cambridge University Press; 1999. pp. 1–86.

Zacca C, Bazzochi A, Pennetta F, et al: Cumulative live birth rate in freeze-all cycles is comparable to that of a conventional embryo transfer policy at the cleavage stage but superior at the blastocyst stage. Fertil Steril 2018; 110:703-9.

Zech NH, Lejeune B, Puissant F, et al. Prospective evaluation of the optimal time for selecting a single embryo for transfer: day 3 versus day 5. Fertil Steril 2007;88:244–6.

Policy implementation and updates

January 2024	Origination. Changed the code 83520 Anti-Mullerian Hormone to 82166.
March 2024	Updated definition of Infertility
April 2024	Added clarifying language to criteria: If a member meets appropriate clinical scenarios with supporting provider documentation, approval may be granted for IUI treatments with oral medications and triggers.
December 2024	Added coverage criteria for ART and IVF (implementation 1/1/25). Added background information. Added and updated references.
February 2025	Updates to policy: removal of criteria relating to multiple blastocyte transfer
	update to criteria for non-covered indications in Assisted Reproductive Technologies
May 2025	Added CPT 55899 Unlisted Procedure, Male Genital System

<p>January 1, 2026</p>	<p>Removal of gender affirmation as a qualifying criterion for infertility services.</p> <p>Moved general indications for infertility treatment and natural cycle indications from criteria section to Background section.</p> <p>Removed statement, “Cumulus cell removal is part of ICSI process”.</p> <p>Clarification of Iatrogenic Infertility coverage for the High Plan.</p> <p>Added links relating to preimplantation genetic testing medical review and preauthorization.</p> <p>Clarified semen analysis collection timeframe to 4 weeks apart.</p> <p>Clarified criteria language relating to recurrent pregnancy loss and aneuploidy.</p> <p>Removed limiting criteria relating to TESE for non-obstructive azoospermia.</p> <p>Clarification of limiting criteria for embryo and oocyte cryopreservation.</p> <p>Clarification of recommendations for a favorable eSET prognosis. Benefit language clarification for Iatrogenic Infertility coverage:</p> <p>Benefits are limited to one successful cycle of fertility preservation for Iatrogenic Infertility per covered person during the entire period of time enrolled for coverage under the healthcare plan.</p> <p>Successful fertility preservation cycle includes:</p> <ol style="list-style-type: none"> 1. 8-10 mature oocytes obtained within no more than 3 attempts of retrieval or 2. 3-4 vials of sperm obtained within no more than 3 attempts of separate sperm extraction sessions. (ASRM, 2019)
------------------------	--